Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 172 results for "Tecfidera Treated Patients"

New Data from ENDORSE Show Positive Results Continued over Fiv...

Long-term Favorable Safety Profile Sustained in Patients Treated with TECFIDERA Positive Clinical and MRI Outcomes in Newly Diagnosed Patients CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 11, 2014-- Today Biogen Idec (NASDAQ: BIIB) announced that ... BusinessWeek, 1 month ago
[x]  

New oral MS treatment Tecfidera approved for use in England and Wales

Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in England and Wales, the National Institute for Health and Care Excellence (NICE) has announced. The NHS must now begin funding this treatment for eligible ...
 Multiple Sclerosis Society1 month ago
Boston Globe

Biogen Idec prices new multiple sclerosis treatment at $62,036 per year

Cambridge biotech Biogen Idec Inc. said Friday it will charge $62,036 per patient for a year's treatment with its newly approved multiple sclerosis drug Plegridy. The list price of Plegridy, a new type of injectable drug that treats adults with the ...
 Boston Globe2 weeks ago Biogen Idec Announces Strides In Clinical Studies For MS Treatments  Bioresearch Online1 month ago NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate)  FirstWord Pharma1 month ago FDA approves new injectable multiple sclerosis treatment from Cambridge's Biogen Idec  Boston Globe2 months ago
[x]  
Globes

Making Treatment Decisions When There Is an Abundance of Options

Despite the benefit of having more choices than ever before to treat patients with multiple sclerosis (MS), the abundance of options has led to more complexity, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, ...
 American Journal of Managed Care1 month ago Multiple Sclerosis Drugs Could Transform Market Again  Investor's Business Daily3 weeks ago New Biogen MS drug challenges Copaxone  Globes1 month ago
Motley Fool

Forward Pharma's Threat To Biogen Idec's Tecfidera

Summary Biogen Idec is increasingly reliant on Tecfidera sales. A Danish biotech is developing a compound with the same active ingredient. Biogen Idec's legal department might have a serious problem. With last year's launch of oral therapy, ...
 Seeking Alpha19 hours ago Why Biogen Stock Is Still An Investment Opportunity  Seeking Alpha4 weeks ago Why Biogen Idec Inc's Stock is Up 17% in 2014  Motley Fool1 month ago

Forward Strides For Forward Pharma At Its IPO

Summary FWP, a Danish biopharmaceutical firm focused on treatments for multiple sclerosis (MS), plans have its IPO this week. FWP will offer 9,523,810 shares at an expected price range of $20 to $22; lead underwriters are Jeffries LLC, Leerink ...
 Seeking Alpha6 days ago IPO Preview: Forward Pharma A/S  Seeking Alpha6 days ago Forward Pharma pulls off a $221M IPO with eyes on unseating Biogen  FierceBiotech5 days ago IPO Report: Forward Pharma A/S (FWP)  Equities.com6 days ago

5 Things Biogen Idec Inc's Management Wants You to Know

1."Our core multiple sclerosis franchise performed remarkably well, and we continue to see an increasing number of patients using our therapies." -- George Scangos, Biogen Idec's CEO When Biogen Idec launched its oral multiple sclerosis drug ...
 Motley Fool1 month ago
Boston Globe

FDA okays Genzyme pill for Gaucher disease

Federal regulators Tuesday okayed for US sale a Genzyme experimental capsule that could become the top-selling pill to treat the rare genetic disorder Gaucher disease. Food and Drug Administration approval of the drug candidate, called Cerdelga, ...
 Boston Globe2 months ago

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

The recent market sell-off spared no sector, and the top biotechnology stocks were treated with their own trip to the woodshed. Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech ...
 24/7 Wall St1 week ago The 5 Best Biotech Stocks in 2014...so far  Motley Fool3 weeks ago

dimethyl fumarate (Tecfidera)

Pharmacy Author: Omudhome Ogbru, PharmD Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University ...
 MedicineNet.com2 months ago Battle Between Biogen And Forward Pharma Continues  Bidness Etc2 weeks ago Forward Pharma Begins Underwriting IPO To Battle Biogen  Bidness Etc2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less